Articoli con mandati relativi all'accesso pubblico - Michael Vogelbaum MD, PhDUlteriori informazioni
Non disponibili pubblicamente: 10
Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes
B Raychaudhuri, P Rayman, P Huang, M Grabowski, D Hambardzumyan, ...
Journal of neuro-oncology 122, 293-301, 2015
Mandati: US National Institutes of Health
RANO 2.0: update to the response assessment in neuro-oncology criteria for high-and low-grade gliomas in adults
PY Wen, M van den Bent, G Youssef, TF Cloughesy, BM Ellingson, ...
Journal of Clinical Oncology 41 (33), 5187-5199, 2023
Mandati: US National Institutes of Health, American Brain Tumor Association
Correcting the drug development paradigm for glioblastoma requires serial tissue sampling
K Singh, KM Hotchkiss, IF Parney, J De Groot, S Sahebjam, N Sanai, ...
Nature medicine 29 (10), 2402-2405, 2023
Mandati: US National Institutes of Health, Cancer Research UK, UK Medical Research …
ONGOING CLINICAL TRIALS
M Groves, J DeGroot, I Tremont, A Forman, S Kang, B Pei, W Julie, ...
Neuro-oncology 13 (Suppl 3), iii85-iii91, 2011
Mandati: US National Institutes of Health
Anti-glioma efficacy and mechanism of action of tripolinolate A from Tripolium pannonicum
W Chai, L Chen, XY Lian, Z Zhang
Planta Medica 84 (11), 786-794, 2018
Mandati: National Natural Science Foundation of China
RBTT-11. NRG Oncology NRG-BN006: A Phase II/III randomized, open-label study of Toca 511 and Toca FC with standard of care compared to standard of care in patients with newly …
M Ahluwalia, S Pugh, B Ellingson, R Kotecha, T Cloughesy, ...
Neuro-oncology 21 (Supplement_6), vi220-vi221, 2019
Mandati: US National Institutes of Health
Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 2: recommendations for standardisation, validation, and good clinical practice
S Bakas, P Vollmuth, N Galldiks, TC Booth, HJWL Aerts, WL Bi, B Wiestler, ...
The Lancet Oncology 25 (11), e589-e601, 2024
Mandati: UK Engineering and Physical Sciences Research Council, UK Medical Research …
Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 1: review of current advancements
JE Villanueva-Meyer, S Bakas, P Tiwari, JM Lupo, E Calabrese, ...
The Lancet Oncology 25 (11), e581-e588, 2024
Mandati: UK Engineering and Physical Sciences Research Council, UK Medical Research …
Let the Guard Down: cAMP Activators Can Improve Immunotherapy in GBM
J Lee, KE Kay, MA Vogelbaum, JD Lathia
Cancer Immunology Research 11 (10), 1300-1301, 2023
Mandati: US National Institutes of Health
NIMG-77. IMPACT OF POST-SURGICAL ENHANCING TUMOR VOLUME AND T2/FLAIR VOLUME ON THE SURVIVAL IMPACT OF BEVACIZUMAB IN NRG ONCOLOGY/RTOG 0825
M Vogelbaum, K Swanson, P Zhang, D Cahill, A Hawkins-Daarud, ...
Neuro-oncology 19 (Suppl 6), vi159, 2017
Mandati: US National Institutes of Health
Disponibili pubblicamente: 87
A randomized trial of bevacizumab for newly diagnosed glioblastoma
MR Gilbert, JJ Dignam, TS Armstrong, JS Wefel, DT Blumenthal, ...
New England Journal of Medicine 370 (8), 699-708, 2014
Mandati: US National Institutes of Health
Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review
L Rogers, I Barani, M Chamberlain, TJ Kaley, M McDermott, J Raizer, ...
Journal of neurosurgery 122 (1), 4-23, 2015
Mandati: US National Institutes of Health
Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials
BM Ellingson, M Bendszus, J Boxerman, D Barboriak, BJ Erickson, ...
Neuro-oncology 17 (9), 1188-1198, 2015
Mandati: US National Institutes of Health
Response assessment in neuro-oncology clinical trials
PY Wen, SM Chang, MJ Van den Bent, MA Vogelbaum, DR Macdonald, ...
Journal of Clinical Oncology 35 (21), 2439-2449, 2017
Mandati: US National Institutes of Health
Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma
B Raychaudhuri, P Rayman, J Ireland, J Ko, B Rini, EC Borden, J Garcia, ...
Neuro-oncology 13 (6), 591-599, 2011
Mandati: US National Institutes of Health
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3 …
MJ van den Bent, B Baumert, SC Erridge, MA Vogelbaum, AK Nowak, ...
The Lancet 390 (10103), 1645-1653, 2017
Mandati: US National Institutes of Health, Cancer Research UK, UK Medical Research …
End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria
MJ van den Bent, MA Vogelbaum, PY Wen, DR Macdonald, SM Chang
Journal of Clinical Oncology 27 (18), 2905-2908, 2009
Mandati: US National Institutes of Health
Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539
L Rogers, P Zhang, MA Vogelbaum, A Perry, LS Ashby, JM Modi, ...
Journal of neurosurgery 129 (1), 35-47, 2017
Mandati: US National Institutes of Health
Historical benchmarks for medical therapy trials in surgery-and radiation-refractory meningioma: a RANO review
T Kaley, I Barani, M Chamberlain, M McDermott, K Panageas, J Raizer, ...
Neuro-oncology 16 (6), 829-840, 2014
Mandati: US National Institutes of Health
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 …
MJ van den Bent, CMS Tesileanu, W Wick, M Sanson, AA Brandes, ...
The Lancet Oncology 22 (6), 813-823, 2021
Mandati: US National Institutes of Health, Cancer Research UK, UK Medical Research …
Le informazioni sulla pubblicazione e sul finanziamento vengono stabilite automaticamente da un software